Ocugen announced it will present on its innovative modifier gene therapy platform at several investor and industry conferences in July 2026. The company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Day on July 10, and its executives will join a panel on regenerative approaches in retinal disease at the OIS Retina Innovation Summit in Montreal on July 14. At the ASRS meeting on July 17, one-year results from the Phase 2 ArMaDa trial of OCU410 will be presented, along with a separate analysis of quantitative FAF/SD-OCT and safety outcomes from the Phase 1/2 study of OCU410. A webcast of the Piper Sandler presentation will be available on the company's investor relations website for 30 days.
Ocugen IncOcugen will present positive Phase 2 trial results and its modifier gene therapy platform at multiple industry conferences, highlighting technological progress.